Work

Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective

Year: 2008

Type: article

Abstract: The Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial was the first trial to compare the cardiovascular outcomes of initial fixed-dose combination angiotensin-converting enzyme inhibitor (ACEI)/calcium channel blocker (CCB) and ACEI/diuretic therapy in patients with hypertension and high risk of cardiovascular events. The initial combination therapy was effective in this population, with ACEI/CCB therapy providing the greatest benefit (reduction in risk of cardiovascular events). Whether or not the findings of ACCOMPLISH can be applied to other renin-angiotensin-aldosterone system (RAAS) inhibitor/CCB combinations, such as angiotensin receptor blocker (ARB)/CCB combinations, has yet to be investigated. The present report reviews the results of ACCOMPLISH, data from trials comparing ARB and ACEI therapies, and findings from studies of ARB/CCB combination therapy that support the use and further study of combination therapy with RAAS inhibitors and CCBs.

Source: Blood Pressure

DOI: 10.1080/08037050802565171

Authors: Sverre E. Kjeldsen, Michael Weber, Suzanne Oparil, Kenneth A. Jamerson

Institutions: University of Oslo, University of Michigan, Michigan Medicine, SUNY Downstate Health Sciences University, University of Alabama, University of Alabama at Birmingham

Language: English

Topic: Blood Pressure and Hypertension Studies

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2055259683

FWCI: 0.66

Cites: 43

Cited by: 7

Related to: 10